The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Is your brain aging faster than your chronological age? New research shows it could raise your risk of death and dementia significantly—and offers promise for early intervention.

A cardiologist spotlights cardiac amyloidosis, a protein disease often mistaken for hypertension. Learn the signs and how to get screened.